121 related articles for article (PubMed ID: 35381788)
1. Can a signature molecular-profile define disparate survival in BRAF-positive Gliosarcoma and identify novel targets for therapeutic intervention?
Gandhi P; Khare R; Garg N; Mishra J
J Cancer Res Ther; 2022; 18(1):224-230. PubMed ID: 35381788
[TBL] [Abstract][Full Text] [Related]
2. Genomic landscape of gliosarcoma: distinguishing features and targetable alterations.
Zaki MM; Mashouf LA; Woodward E; Langat P; Gupta S; Dunn IF; Wen PY; Nahed BV; Bi WL
Sci Rep; 2021 Sep; 11(1):18009. PubMed ID: 34504233
[TBL] [Abstract][Full Text] [Related]
3. Primary and secondary gliosarcomas: clinical, molecular and survival characteristics.
Cachia D; Kamiya-Matsuoka C; Mandel JJ; Olar A; Cykowski MD; Armstrong TS; Fuller GN; Gilbert MR; De Groot JF
J Neurooncol; 2015 Nov; 125(2):401-10. PubMed ID: 26354773
[TBL] [Abstract][Full Text] [Related]
4. Gliosarcoma vs. glioblastoma: a retrospective case series using molecular profiling.
Dardis C; Donner D; Sanai N; Xiu J; Mittal S; Michelhaugh SK; Pandey M; Kesari S; Heimberger AB; Gatalica Z; Korn MW; Sumrall AL; Phuphanich S
BMC Neurol; 2021 Jun; 21(1):231. PubMed ID: 34162346
[TBL] [Abstract][Full Text] [Related]
5. A rare case of BRAF V600E-mutated epithelioid glioblastoma with a sarcomatous component.
Ishikawa R; Kadota K; Hayashi T; Kimura N; Inoue K; Ibuki E; Kagawa S; Kushida Y; Okada M; Miyake K; Tamiya T; Nobusawa S; Hirato J; Haba R
Pathol Int; 2020 Mar; 70(3):166-170. PubMed ID: 31903645
[TBL] [Abstract][Full Text] [Related]
6. An IDH1-mutated primary gliosarcoma: case report.
Hsieh JK; Hong CS; Manjila S; Cohen ML; Lo S; Rogers L; Sloan AE
J Neurosurg; 2017 Feb; 126(2):476-480. PubMed ID: 27153165
[TBL] [Abstract][Full Text] [Related]
7. Gliosarcoma: a histologic and immunohistochemical reaffirmation.
Meis JM; Ho KL; Nelson JS
Mod Pathol; 1990 Jan; 3(1):19-24. PubMed ID: 2155418
[TBL] [Abstract][Full Text] [Related]
8. High prevalence of TP53 mutations is associated with poor survival and an EMT signature in gliosarcoma patients.
Cho SY; Park C; Na D; Han JY; Lee J; Park OK; Zhang C; Sung CO; Moon HE; Kim Y; Kim JH; Kim JJ; Khang SK; Nam DH; Choi JW; Suh YL; Kim DG; Park SH; Youn H; Yun K; Kim JI; Lee C; Paek SH; Park H
Exp Mol Med; 2017 Apr; 49(4):e317. PubMed ID: 28408749
[TBL] [Abstract][Full Text] [Related]
9. Novel molecular panel for evaluating systemic inflammation and survival in therapy naïve glioma patients.
Gandhi P; Shrivastava R; Garg N; Sorte SK
World J Clin Oncol; 2021 Oct; 12(10):947-959. PubMed ID: 34733616
[TBL] [Abstract][Full Text] [Related]
10. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
[TBL] [Abstract][Full Text] [Related]
11. Gliosarcomas lack BRAF
Schwetye KE; Joseph NM; Al-Kateb H; Rich KM; Schmidt RE; Perry A; Gutmann DH; Dahiya S
Neuropathology; 2016 Oct; 36(5):448-455. PubMed ID: 26932501
[TBL] [Abstract][Full Text] [Related]
12. Gliosarcomas with the
Wang L; Sun J; Li Z; Chen L; Fu Y; Zhao L; Liu L; Wei Y; Teng L; Lu D
J Clin Pathol; 2017 Dec; 70(12):1079-1083. PubMed ID: 28775171
[TBL] [Abstract][Full Text] [Related]
13. Molecular signature of stem-like glioma cells (SLGCs) from human glioblastoma and gliosarcoma.
Zechel C; Loy M; Wegner C; Dahlke E; Soetje B; Baehr L; Leppert J; Ostermaier JJ; Lueg T; Nielsen J; Elßner J; Willeke V; Marzahl S; Tronnier V; Madany Mamlouk A
PLoS One; 2024; 19(2):e0291368. PubMed ID: 38306361
[TBL] [Abstract][Full Text] [Related]
14. Gliosarcoma with prominent smooth muscle component (gliomyosarcoma): a report of 10 cases.
Khanna M; Siraj F; Chopra P; Bhalla S; Roy S
Indian J Pathol Microbiol; 2011; 54(1):51-4. PubMed ID: 21393877
[TBL] [Abstract][Full Text] [Related]
15. Radiation-induced gliomas: a report of four cases and analysis of molecular biomarkers.
Nakao T; Sasagawa Y; Nobusawa S; Takabatake Y; Sabit H; Kinoshita M; Miyashita K; Hayashi Y; Yokoo H; Nakada M
Brain Tumor Pathol; 2017 Oct; 34(4):149-154. PubMed ID: 28795231
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of telomerase-associated parameters in glioblastoma: effect of patient age.
Lötsch D; Ghanim B; Laaber M; Wurm G; Weis S; Lenz S; Webersinke G; Pichler J; Berger W; Spiegl-Kreinecker S
Neuro Oncol; 2013 Apr; 15(4):423-32. PubMed ID: 23393205
[TBL] [Abstract][Full Text] [Related]
17. Clinical and survival characteristics of primary and secondary gliosarcoma patients.
Amer A; Khose S; Alhasan H; Pokhylevych H; Fuller G; Chasen N; de Groot J; Johnson JM
Clin Neurol Neurosurg; 2022 Mar; 214():107146. PubMed ID: 35101778
[TBL] [Abstract][Full Text] [Related]
18. Evaluating the potential of circulating hTERT levels in glioma: can plasma levels serve as an independent prognostic marker?
Gandhi P; Khare R; Garg N
J Neurooncol; 2017 Nov; 135(2):255-261. PubMed ID: 28756592
[TBL] [Abstract][Full Text] [Related]
19. Gliosarcoma with PNET features mimicking a metastatic neuroendocrine carcinoma: A diagnostic dilemma.
McGahan BG; Toop N; Ward S; Jones D; Kobalka PJ; Palmer JD; Elder JB
Clin Neuropathol; 2021; 40(5):279-285. PubMed ID: 34190681
[TBL] [Abstract][Full Text] [Related]
20. Clinical usefulness of serum telomerase reverse transcriptase (hTERT) mRNA and epidermal growth factor receptor (EGFR) mRNA as a novel tumor marker for lung cancer.
Miura N; Nakamura H; Sato R; Tsukamoto T; Harada T; Takahashi S; Adachi Y; Shomori K; Sano A; Kishimoto Y; Ito H; Hasegawa J; Shiota G
Cancer Sci; 2006 Dec; 97(12):1366-73. PubMed ID: 17052260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
